Neuren Pharmaceuticals Limited
Appendix 4D Half-Year Financial Report
30 June 2020

On August 25, 2021 Neuren Pharmaceuticals Limited ("Neuren" or the "Company") reported this financial report, including the interim consolidated financial statements, for the six months ended 30 June 2020, with the six months ended 30 June 2019 as the comparative period.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2. Results for announcement to the market

The Group’s net loss after tax for the half-year ended 30 June 2020 was $4.8 million, compared with $7.9 million for the half-year ended 30 June 2019, predominately due to a decrease of $2.7 million in research and development costs. This was due to lower expenditure for manufacturing and non-clinical activities relating to the Rett Syndrome Phase 3 trial, partially offset by an increase in expenditure in 2020 for the NNZ-2591 non-clinical studies and Phase 1 trial, including manufacture of the required drug.

A more detailed discussion of the activities undertaken in the period is set out in the Directors’ Report contained in the attached Interim Report.

3. Net Tangible Assets per Security

4. Entities over which control has been gained or lost during the period: None.

5. Details of dividends Not applicable.

6. Details of dividend reinvestment plans Not applicable.

7. Details of associates and joint venture entities None.

8. Accounting standards The interim financial statements have been prepared in accordance with generally accepted accounting practice in New Zealand and NZ IAS 34 Interim Financial Reporting.

9. Auditors review
The interim financial statements have been subject to independent review by the Company’s auditors. The unqualified review report is included in the attached Interim Report